Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Largest borrow rate increases among liquid names » 08:45
08/10/20
08/10
08:45
08/10/20
08:45
MVIS

MicroVision

$1.72 /

-0.16 (-8.51%)

, DGLY

Digital Ally

$3.21 /

-0.125 (-3.75%)

, XSPA

XpresSpa

$4.18 /

-0.1 (-2.34%)

, NBRV

Nabriva Therapeutics

$0.73 /

-0.0775 (-9.60%)

, TAN

Claymore/MAC Global Solar Energy Index

$51.18 /

+1.06 (+2.11%)

, AMTD

TD Ameritrade

$36.86 /

+1.02 (+2.85%)

, QGEN

Qiagen

$47.21 /

+0.35 (+0.75%)

, LILAK

Liberty Latin America

$9.26 /

+0.405 (+4.57%)

, OIH

Oil Services Holders Trust

$134.23 /

+0.49 (+0.37%)

, UPRO

Uproar Inc

$56.17 /

+0.17 (+0.30%)

Latest data shows the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
XSPA XpresSpa
$4.18 /

-0.1 (-2.34%)

UPRO Uproar Inc
$56.17 /

+0.17 (+0.30%)

QGEN Qiagen
$47.21 /

+0.35 (+0.75%)

OIH Oil Services Holders Trust
$134.23 /

+0.49 (+0.37%)

NBRV Nabriva Therapeutics
$0.73 /

-0.0775 (-9.60%)

MVIS MicroVision
$1.72 /

-0.16 (-8.51%)

DGLY Digital Ally
$3.21 /

-0.125 (-3.75%)

AMTD TD Ameritrade
$36.86 /

+1.02 (+2.85%)

MVIS MicroVision
$1.72 /

-0.16 (-8.51%)

05/06/20 Craig-Hallum
MicroVision rise driven by Microsoft speculation, says Craig-Hallum
02/26/20 Craig-Hallum
MicroVision downgraded to Hold from Buy at Craig-Hallum
02/26/20 H.C. Wainwright
MicroVision downgraded to Neutral from Buy at H.C. Wainwright
02/26/20 Ladenburg
Ladenburg downgrades MicroVision to Neutral on lost contract
DGLY Digital Ally
$3.21 /

-0.125 (-3.75%)

06/29/20 Aegis
Digital Ally initiated with a Buy at Aegis
XSPA XpresSpa
$4.18 /

-0.1 (-2.34%)

NBRV Nabriva Therapeutics
$0.73 /

-0.0775 (-9.60%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
TAN Claymore/MAC Global Solar Energy Index
$51.18 /

+1.06 (+2.11%)

AMTD TD Ameritrade
$36.86 /

+1.02 (+2.85%)

07/24/20 Morgan Stanley
Morgan Stanley says Schwab share price doesn't reflect TD Ameritrade benefits
07/09/20 Wolfe Research
TD Ameritrade upgraded to Peer Perform from Underperform at Wolfe Research
06/08/20 Wolfe Research
TD Ameritrade downgraded to Underperform from Outperform at Wolfe Research
05/21/20 BofA
Charles Schwab downgraded to Neutral from Buy at BofA
QGEN Qiagen
$47.21 /

+0.35 (+0.75%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
LILAK Liberty Latin America
$9.26 /

+0.405 (+4.57%)

05/20/20 Citi
Liberty Latin America price target lowered to $12 from $18 at Citi
10/04/19 Citi
Liberty Latin America transferred with a Buy rating at Citi
OIH Oil Services Holders Trust
$134.23 /

+0.49 (+0.37%)

UPRO Uproar Inc
$56.17 /

+0.17 (+0.30%)

QGEN Qiagen
$47.21 /

+0.35 (+0.75%)

NBRV Nabriva Therapeutics
$0.73 /

-0.0775 (-9.60%)

MVIS MicroVision
$1.72 /

-0.16 (-8.51%)

LILAK Liberty Latin America
$9.26 /

+0.405 (+4.57%)

DGLY Digital Ally
$3.21 /

-0.125 (-3.75%)

AMTD TD Ameritrade
$36.86 /

+1.02 (+2.85%)

  • 08
    Jun
  • 02
    Jun
  • 28
    Feb
QGEN Qiagen
$47.21 /

+0.35 (+0.75%)

MVIS MicroVision
$1.72 /

-0.16 (-8.51%)

DGLY Digital Ally
$3.21 /

-0.125 (-3.75%)

AMTD TD Ameritrade
$36.86 /

+1.02 (+2.85%)

XSPA XpresSpa
$4.18 /

-0.1 (-2.34%)

QGEN Qiagen
$47.21 /

+0.35 (+0.75%)

NBRV Nabriva Therapeutics
$0.73 /

-0.0775 (-9.60%)

MVIS MicroVision
$1.72 /

-0.16 (-8.51%)

DGLY Digital Ally
$3.21 /

-0.125 (-3.75%)

AMTD TD Ameritrade
$36.86 /

+1.02 (+2.85%)

XSPA XpresSpa
$4.18 /

-0.1 (-2.34%)

UPRO Uproar Inc
$56.17 /

+0.17 (+0.30%)

QGEN Qiagen
$47.21 /

+0.35 (+0.75%)

OIH Oil Services Holders Trust
$134.23 /

+0.49 (+0.37%)

NBRV Nabriva Therapeutics
$0.73 /

-0.0775 (-9.60%)

MVIS MicroVision
$1.72 /

-0.16 (-8.51%)

DGLY Digital Ally
$3.21 /

-0.125 (-3.75%)

Conference/Events
Wells Fargo to hold a virtual forum » 08:31
08/10/20
08/10
08:31
08/10/20
08:31
ACIW

ACI Worldwide

$30.51 /

-0.43 (-1.39%)

, BKI

Black Knight

$76.74 /

+1.09 (+1.44%)

, CATM

Cardtronics

$21.41 /

-2.825 (-11.66%)

, CDLX

Cardlytics

$66.18 /

-1.54 (-2.27%)

, DNB

Dun & Bradstreet

$26.03 /

+1.03 (+4.12%)

, EEFT

Euronet

$100.49 /

-0.47 (-0.47%)

, EFX

Equifax

$166.71 /

+4.17 (+2.57%)

, FDS

FactSet

$355.27 /

+1.77 (+0.50%)

, FICO

Fair Isaac

$441.83 /

+0.595 (+0.13%)

, FIS

FIS

$147.77 /

+0.95 (+0.65%)

, FORR

Forrester

$37.32 /

+1.61 (+4.51%)

, IBM

IBM

$124.97 /

+2.12 (+1.73%)

, INFO

IHS Markit

$84.00 /

+1.26 (+1.52%)

, IT

Gartner

$131.36 /

+0.78 (+0.60%)

, J

Jacobs

$91.23 /

+0.865 (+0.96%)

, MANT

ManTech

$72.27 /

+1.24 (+1.75%)

, MCO

Moody's

$275.63 /

-3.71 (-1.33%)

, NLSN

Nielsen

$15.89 /

+0.495 (+3.22%)

, PBI

Pitney Bowes

$6.27 /

+0.65 (+11.57%)

, PSN

Parsons

$34.97 /

-0.29 (-0.82%)

, PYPL

PayPal

$198.72 /

-5.39 (-2.64%)

, SPGI

S&P Global

$347.27 /

-5.32 (-1.51%)

, TRU

TransUnion

$87.33 /

+0.8 (+0.92%)

, WEC

WEC Energy

$94.30 /

+1.29 (+1.39%)

, WEX

Wex

$162.79 /

-5.655 (-3.36%)

, WFC

Wells Fargo

$25.06 /

+0.81 (+3.34%)

, WU

Western Union

$23.27 /

+0.51 (+2.24%)

, ZIP

Zipcar

$0.00 /

+ (+0.00%)

Virtual 5th Annual…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WU Western Union
$23.27 /

+0.51 (+2.24%)

WFC Wells Fargo
$25.06 /

+0.81 (+3.34%)

WEX Wex
$162.79 /

-5.655 (-3.36%)

WEC WEC Energy
$94.30 /

+1.29 (+1.39%)

TRU TransUnion
$87.33 /

+0.8 (+0.92%)

SPGI S&P Global
$347.27 /

-5.32 (-1.51%)

PYPL PayPal
$198.72 /

-5.39 (-2.64%)

PSN Parsons
$34.97 /

-0.29 (-0.82%)

PBI Pitney Bowes
$6.27 /

+0.65 (+11.57%)

NLSN Nielsen
$15.89 /

+0.495 (+3.22%)

MCO Moody's
$275.63 /

-3.71 (-1.33%)

MANT ManTech
$72.27 /

+1.24 (+1.75%)

J Jacobs
$91.23 /

+0.865 (+0.96%)

IT Gartner
$131.36 /

+0.78 (+0.60%)

INFO IHS Markit
$84.00 /

+1.26 (+1.52%)

IBM IBM
$124.97 /

+2.12 (+1.73%)

FORR Forrester
$37.32 /

+1.61 (+4.51%)

FIS FIS
$147.77 /

+0.95 (+0.65%)

FICO Fair Isaac
$441.83 /

+0.595 (+0.13%)

FDS FactSet
$355.27 /

+1.77 (+0.50%)

EFX Equifax
$166.71 /

+4.17 (+2.57%)

EEFT Euronet
$100.49 /

-0.47 (-0.47%)

CDLX Cardlytics
$66.18 /

-1.54 (-2.27%)

CATM Cardtronics
$21.41 /

-2.825 (-11.66%)

BKI Black Knight
$76.74 /

+1.09 (+1.44%)

ACIW ACI Worldwide
$30.51 /

-0.43 (-1.39%)

ACIW ACI Worldwide
$30.51 /

-0.43 (-1.39%)

08/07/20 Canaccord
ACI Worldwide price target raised to $40 from $35 at Canaccord
07/07/20 Canaccord
ACI Worldwide product portfolio increases confidence, says Canaccord
05/29/20 Needham
ACI Worldwide initiated with a Buy at Needham
05/08/20 Canaccord
ACI Worldwide price target lowered to $35 from $44 at Canaccord
BKI Black Knight
$76.74 /

+1.09 (+1.44%)

07/23/20 Keefe Bruyette
Black Knight upgraded to Outperform from Market Perform at Keefe Bruyette
06/29/20 Zelman
Black Knight added as Buy to Top Idea Basket at Zelman
05/06/20 Stephens
Stephens names Black Knight as a Best Idea
05/06/20 Wells Fargo
Black Knight price target raised to $85 from $80 at Wells Fargo
CATM Cardtronics
$21.41 /

-2.825 (-11.66%)

05/22/20
Fly Intel: Top five analyst initiations
05/22/20 Truist
Cardtronics price target raised to $35 from $29 at SunTrust
05/22/20 Gabelli
Cardtronics initiated with a Buy at Gabelli
04/21/20 DA Davidson
Cardtronics price target lowered to $40 from $51 at DA Davidson
CDLX Cardlytics
$66.18 /

-1.54 (-2.27%)

08/05/20 Craig-Hallum
Cardlytics price target raised to $70 from $50 at Craig-Hallum
07/09/20 Truist
Cardlytics price target raised to $75 from $55 at SunTrust
05/12/20 Craig-Hallum
Cardlytics price target lowered to $50 from $70 at Craig-Hallum
05/12/20 Truist
Cardlytics price target raised to $55 from $50 at SunTrust
DNB Dun & Bradstreet
$26.03 /

+1.03 (+4.12%)

07/28/20 Citi
Dun & Bradstreet initiated with a Neutral at Citi
07/27/20 JPMorgan
Dun & Bradstreet initiated with a Neutral at JPMorgan
07/27/20 Wells Fargo
Dun & Bradstreet initiated with an Equal Weight at Wells Fargo
07/27/20 Deutsche Bank
Dun & Bradstreet initiated with a Buy at Deutsche Bank
EEFT Euronet
$100.49 /

-0.47 (-0.47%)

07/14/20 Goldman Sachs
Euronet initiated with a Neutral at Goldman Sachs
06/19/20 Citi
Euronet downgraded to Neutral after faster than expected bounce at Citi
06/19/20 Citi
Euronet downgraded to Neutral from Buy at Citi
06/03/20 Truist
Euronet price target raised to $135 from $115 at SunTrust
EFX Equifax
$166.71 /

+4.17 (+2.57%)

07/23/20 Deutsche Bank
Equifax price target raised to $170 from $159 at Deutsche Bank
07/10/20 Exane BNP Paribas
Equifax downgraded to Neutral from Outperform at Exane BNP Paribas
06/10/20 Barclays
Equifax price target raised to $175 from $110 at Barclays
06/09/20 JPMorgan
Equifax price target raised to $195 from $150 at JPMorgan
FDS FactSet
$355.27 /

+1.77 (+0.50%)

06/26/20 DA Davidson
FactSet price target raised to $288 from $260 at DA Davidson
06/11/20 Northcoast
FactSet downgraded to Sell ahead of earnings at Northcoast
06/11/20 Northcoast
FactSet downgraded to Sell from Neutral at Northcoast
06/09/20 DA Davidson
FactSet price target raised to $260 from $225 at DA Davidson
FICO Fair Isaac
$441.83 /

+0.595 (+0.13%)

07/30/20 Wells Fargo
Fair Isaac price target raised to $550 from $475 at Wells Fargo
07/30/20 Baird
Fair Isaac price target raised to $486 from $460 at Baird
07/14/20 Jefferies
Fair Isaac price target raised to $393 from $362 at Jefferies
07/10/20 Wells Fargo
Fair Isaac price target raised to $475 from $400 at Wells Fargo
FIS FIS
$147.77 /

+0.95 (+0.65%)

08/05/20 Credit Suisse
FIS price target raised to $160 from $150 at Credit Suisse
08/05/20 Wells Fargo
FIS price target raised to $165 from $150 at Wells Fargo
08/05/20 Stephens
FIS price target raised to $174 from $164 at Stephens
08/03/20 KeyBanc
FIS price target raised to $165 from $140 at KeyBanc
FORR Forrester
$37.32 /

+1.61 (+4.51%)

08/03/20 Barrington
Forrester price target raised to $44 from $40 at Barrington
03/31/20 Barrington
Forrester upgraded to Outperform from Market Perform at Barrington
08/28/19 Sidoti
Forrester initiated with a Buy at Sidoti
IBM IBM
$124.97 /

+2.12 (+1.73%)

07/22/20 Argus
IBM upgraded to Buy from Hold at Argus
07/22/20 Argus
IBM upgraded to Buy from Hold at Argus
07/21/20 Wells Fargo
IBM price target raised to $130 from $120 at Wells Fargo
07/21/20 Morgan Stanley
IBM price target raised to $128 from $111 at Morgan Stanley
INFO IHS Markit
$84.00 /

+1.26 (+1.52%)

06/24/20 Baird
IHS Markit price target raised to $84 from $69 at Baird
06/24/20 Wells Fargo
IHS Markit price target raised to $90 from $70 at Wells Fargo
06/24/20 BMO Capital
IHS Markit price target raised to $82 from $62 at BMO Capital
06/24/20 RBC Capital
IHS Markit price target raised to $90 from $84 at RBC Capital
IT Gartner
$131.36 /

+0.78 (+0.60%)

05/11/20 BMO Capital
Gartner price target raised to $122 from $100 at BMO Capital
03/27/20 BMO Capital
Gartner price target lowered to $100 from $113 at BMO Capital
03/25/20 BMO Capital
Gartner price target lowered to $113 from $121 at BMO Capital
03/10/20 BMO Capital
Gartner price target lowered to $121 from $158 at BMO Capital
J Jacobs
$91.23 /

+0.865 (+0.96%)

07/01/20 Stifel
Jacobs secures 'key strategic, highly competitive' takeaway win, says Stifel
05/12/20 Argus
Jacobs price target lowered to $100 from $116 at Argus
05/11/20 DA Davidson
Jacobs price target lowered to $95 from $110 at DA Davidson
04/27/20 Citi
KBR upgraded to Buy from Neutral at Citi
MANT ManTech
$72.27 /

+1.24 (+1.75%)

07/30/20 Alliance Global Partners
ManTech upgraded to Buy from Neutral at Alliance Global Partners
05/19/20
Fly Intel: Top five analyst upgrades
05/19/20 Wells Fargo
ManTech upgraded to Overweight from Equal Weight at Wells Fargo on valuation
05/19/20 Wells Fargo
ManTech upgraded to Overweight from Equal Weight at Wells Fargo
MCO Moody's
$275.63 /

-3.71 (-1.33%)

07/08/20 Goldman Sachs
Moody's price target raised to $295 from $258 at Goldman Sachs
06/08/20 BMO Capital
Moody's price target raised to $298 from $285 at BMO Capital
05/29/20 Credit Suisse
Moody's initiated with an Outperform at Credit Suisse
05/18/20 Oppenheimer
Moody's initiated with an Outperform at Oppenheimer
NLSN Nielsen
$15.89 /

+0.495 (+3.22%)

05/28/20 Spin-Off Research
Nielsen upgraded to Hold from Sell at Spin-Off Research
05/21/20 Citi
Nielsen price target lowered to $18 from $28 at Citi
04/09/20 Arete
Nielsen downgraded to Sell from Neutral at Arete
02/28/20
Fly Intel: Top five analyst downgrades
PBI Pitney Bowes
$6.27 /

+0.65 (+11.57%)

08/04/20 National Securities
Pitney Bowes price target raised to $6 from $5 at National Securities
08/03/20 National Securities
Pitney Bowes upgraded to Buy from Neutral at National Securities
05/05/20 National Securities
Pitney Bowes downgraded to Neutral from Buy at National Securities
10/24/19
Fly Intel: Top five analyst initiations
PSN Parsons
$34.97 /

-0.29 (-0.82%)

05/05/20 Wells Fargo
Parsons price target raised to $39 from $33 at Wells Fargo
04/15/20 Benchmark
Parsons initiated with a Buy at Benchmark
04/02/20 Wells Fargo
Parsons price target lowered to $33 from $42 at Wells Fargo
03/30/20 William Blair
Parsons initiated with an Outperform at William Blair
PYPL PayPal
$198.72 /

-5.39 (-2.64%)

08/04/20 Stephens
PayPal price target raised to $228 from $194 at Stephens
08/03/20 Barclays
PayPal price target raised to $228 from $210 at Barclays
07/31/20 Keefe Bruyette
PayPal price target raised to $220 from $205 at Keefe Bruyette
07/30/20 Wedbush
PayPal price target raised to $220 from $200 at Wedbush
SPGI S&P Global
$347.27 /

-5.32 (-1.51%)

07/29/20 Oppenheimer
S&P Global price target raised to $396 from $356 at Oppenheimer
07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 Goldman Sachs
S&P Global upgraded to Conviction Buy from Buy at Goldman Sachs
06/08/20 BMO Capital
S&P Global price target raised to $365 from $322 at BMO Capital
TRU TransUnion
$87.33 /

+0.8 (+0.92%)

07/22/20
Fly Intel: Top five analyst upgrades
07/22/20 Baird
TransUnion appears stable to improving, Baird upgrades to Outperform
07/22/20 Baird
TransUnion upgraded to Outperform from Neutral at Baird
06/10/20 Barclays
TransUnion price target raised to $105 from $75 at Barclays
WEC WEC Energy
$94.30 /

+1.29 (+1.39%)

04/24/20 Wells Fargo
WEC Energy downgraded to Equal Weight at Wells Fargo on relative valuation
04/24/20 Wells Fargo
WEC Energy downgraded to Equal Weight from Overweight at Wells Fargo
03/16/20 Evercore ISI
WEC Energy upgraded to In Line from Underperform at Evercore ISI
03/13/20 KeyBanc
WEC Energy upgraded to Overweight from Sector Weight at KeyBanc
WEX Wex
$162.79 /

-5.655 (-3.36%)

08/03/20
Fly Intel: Top five analyst downgrades
08/03/20 Wells Fargo
Wex downgraded on 'more gradual' fundamental rebound at Wells Fargo
08/03/20 Wells Fargo
Wex downgraded to Equal Weight from Overweight at Wells Fargo
07/28/20 Barclays
Wex price target raised to $188 from $163 at Barclays
WFC Wells Fargo
$25.06 /

+0.81 (+3.34%)

07/22/20 Atlantic Equities
Atlantic upgrades Wells Fargo to Neutral post dividend cut
07/22/20 Atlantic Equities
Wells Fargo upgraded to Neutral from Underweight at Atlantic Equities
07/16/20 BMO Capital
Wells Fargo price target lowered to $36 from $41 at BMO Capital
07/15/20
Fly Intel: Top five analyst upgrades
WU Western Union
$23.27 /

+0.51 (+2.24%)

07/30/20 Wolfe Research
Western Union upgraded to Peer Perform from Underperform at Wolfe Research
07/14/20 Goldman Sachs
Western Union initiated with a Sell at Goldman Sachs
07/01/20 Northland
Western Union upgraded to Outperform from Market Perform at Northland
06/10/20
Fly Intel: Top five analyst downgrades
ZIP Zipcar
$0.00 /

+ (+0.00%)

WU Western Union
$23.27 /

+0.51 (+2.24%)

WFC Wells Fargo
$25.06 /

+0.81 (+3.34%)

WEX Wex
$162.79 /

-5.655 (-3.36%)

WEC WEC Energy
$94.30 /

+1.29 (+1.39%)

TRU TransUnion
$87.33 /

+0.8 (+0.92%)

SPGI S&P Global
$347.27 /

-5.32 (-1.51%)

PYPL PayPal
$198.72 /

-5.39 (-2.64%)

PSN Parsons
$34.97 /

-0.29 (-0.82%)

PBI Pitney Bowes
$6.27 /

+0.65 (+11.57%)

NLSN Nielsen
$15.89 /

+0.495 (+3.22%)

MCO Moody's
$275.63 /

-3.71 (-1.33%)

MANT ManTech
$72.27 /

+1.24 (+1.75%)

J Jacobs
$91.23 /

+0.865 (+0.96%)

IT Gartner
$131.36 /

+0.78 (+0.60%)

INFO IHS Markit
$84.00 /

+1.26 (+1.52%)

IBM IBM
$124.97 /

+2.12 (+1.73%)

FORR Forrester
$37.32 /

+1.61 (+4.51%)

FIS FIS
$147.77 /

+0.95 (+0.65%)

FICO Fair Isaac
$441.83 /

+0.595 (+0.13%)

FDS FactSet
$355.27 /

+1.77 (+0.50%)

EFX Equifax
$166.71 /

+4.17 (+2.57%)

EEFT Euronet
$100.49 /

-0.47 (-0.47%)

DNB Dun & Bradstreet
$26.03 /

+1.03 (+4.12%)

CDLX Cardlytics
$66.18 /

-1.54 (-2.27%)

CATM Cardtronics
$21.41 /

-2.825 (-11.66%)

BKI Black Knight
$76.74 /

+1.09 (+1.44%)

ACIW ACI Worldwide
$30.51 /

-0.43 (-1.39%)

  • 01
    Jul
  • 17
    Jun
  • 11
    Sep
WU Western Union
$23.27 /

+0.51 (+2.24%)

WFC Wells Fargo
$25.06 /

+0.81 (+3.34%)

WEC WEC Energy
$94.30 /

+1.29 (+1.39%)

SPGI S&P Global
$347.27 /

-5.32 (-1.51%)

PYPL PayPal
$198.72 /

-5.39 (-2.64%)

NLSN Nielsen
$15.89 /

+0.495 (+3.22%)

J Jacobs
$91.23 /

+0.865 (+0.96%)

IBM IBM
$124.97 /

+2.12 (+1.73%)

EFX Equifax
$166.71 /

+4.17 (+2.57%)

WU Western Union
$23.27 /

+0.51 (+2.24%)

WFC Wells Fargo
$25.06 /

+0.81 (+3.34%)

SPGI S&P Global
$347.27 /

-5.32 (-1.51%)

PYPL PayPal
$198.72 /

-5.39 (-2.64%)

PSN Parsons
$34.97 /

-0.29 (-0.82%)

PBI Pitney Bowes
$6.27 /

+0.65 (+11.57%)

NLSN Nielsen
$15.89 /

+0.495 (+3.22%)

MCO Moody's
$275.63 /

-3.71 (-1.33%)

J Jacobs
$91.23 /

+0.865 (+0.96%)

INFO IHS Markit
$84.00 /

+1.26 (+1.52%)

IBM IBM
$124.97 /

+2.12 (+1.73%)

FIS FIS
$147.77 /

+0.95 (+0.65%)

FDS FactSet
$355.27 /

+1.77 (+0.50%)

EFX Equifax
$166.71 /

+4.17 (+2.57%)

EEFT Euronet
$100.49 /

-0.47 (-0.47%)

DNB Dun & Bradstreet
$26.03 /

+1.03 (+4.12%)

CDLX Cardlytics
$66.18 /

-1.54 (-2.27%)

CATM Cardtronics
$21.41 /

-2.825 (-11.66%)

WU Western Union
$23.27 /

+0.51 (+2.24%)

WFC Wells Fargo
$25.06 /

+0.81 (+3.34%)

WEC WEC Energy
$94.30 /

+1.29 (+1.39%)

PYPL PayPal
$198.72 /

-5.39 (-2.64%)

PBI Pitney Bowes
$6.27 /

+0.65 (+11.57%)

NLSN Nielsen
$15.89 /

+0.495 (+3.22%)

IBM IBM
$124.97 /

+2.12 (+1.73%)

EFX Equifax
$166.71 /

+4.17 (+2.57%)

DNB Dun & Bradstreet
$26.03 /

+1.03 (+4.12%)

CDLX Cardlytics
$66.18 /

-1.54 (-2.27%)

Earnings
Revolution Medicines reports Q2 EPS (46c), consensus (35c) » 07:43
08/10/20
08/10
07:43
08/10/20
07:43
RVMD

Revolution Medicines

$26.26 /

+0.62 (+2.42%)

Reports Q revenue $10M,…

Reports Q revenue $10M, consensus $13.36M. "Revolution Medicines continues pursuit of its ambitious R&D strategy on behalf of cancer patients with RAS-addicted tumors. Our cohesive pipeline focuses on multiple key nodes within RAS signaling and interconnected pathways to enable combination treatment approaches that may be needed to maximize patient benefit in these vexing cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines."In the second quarter, we made broad progress across our portfolio of targeted inhibitors. RMC-4630, our clinical stage inhibitor of SHP2 and a potential backbone in combination treatments, showed further evidence of clinical activity against genetically-defined tumors. Importantly, combination studies of RMC-4630 with the KRASG12C inhibitor, AMG 510, and the checkpoint inhibitor, Keytruda, were initiated. We also introduced a potential role for our second clinical candidate, RMC-5552, in combination therapy against cancers carrying dual RAS/mTOR pathway mutations. Further, we made substantial progress toward nomination of a first development candidate from our innovative family of targeted RAS inhibitors. Finally, just after the quarter, we completed a successful first follow-on financing, further strengthening our financial position to enable the continued advancement of our deep R&D pipeline."

ShowHide Related Items >><<
RVMD Revolution Medicines
$26.26 /

+0.62 (+2.42%)

RVMD Revolution Medicines
$26.26 /

+0.62 (+2.42%)

05/21/20
Fly Intel: Top five analyst initiations
05/21/20 H.C. Wainwright
Revolution Medicines initiated with a Buy at H.C. Wainwright
03/09/20
Fly Intel: Top five analyst initiations
03/09/20 Cowen
Revolution Medicines initiated with an Outperform at Cowen
  • 09
    Jul
  • 13
    Feb
RVMD Revolution Medicines
$26.26 /

+0.62 (+2.42%)

Recommendations
Pacira price target raised to $70 from $68 at H.C. Wainwright » 06:20
08/10/20
08/10
06:20
08/10/20
06:20
PCRX

Pacira

$58.34 /

+0.32 (+0.55%)

H.C. Wainwright analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PCRX Pacira
$58.34 /

+0.32 (+0.55%)

PCRX Pacira
$58.34 /

+0.32 (+0.55%)

07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
PCRX Pacira
$58.34 /

+0.32 (+0.55%)

PCRX Pacira
$58.34 /

+0.32 (+0.55%)

Thursday
Earnings
Chembio Diagnostics reports Q2 EPS (42c), consensus (39c) » 16:47
08/06/20
08/06
16:47
08/06/20
16:47
CEMI

Chembio Diagnostics

$5.42 /

-0.49 (-8.29%)

Reports Q2 revenue $5.1M,…

Reports Q2 revenue $5.1M, consensus $6.88M "Despite challenging circumstances in the quarter, we are optimistic that our scientific expertise and platform flexibility will allow us to develop additional high quality, easy to use point-of-care COVID-19 tests that will contribute to the decentralization of testing. Central laboratories are currently facing extreme testing volumes that are creating delays in returning results to patients and our technology can contribute to improving the current situation," said Richard Eberly, Chembio's President and Chief Executive Officer. "I am proud of the resiliency and dedication of our team over the past months. We are excited about the opportunities ahead of us."

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$5.42 /

-0.49 (-8.29%)

CEMI Chembio Diagnostics
$5.42 /

-0.49 (-8.29%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$5.42 /

-0.49 (-8.29%)

  • 07
    May
CEMI Chembio Diagnostics
$5.42 /

-0.49 (-8.29%)

CEMI Chembio Diagnostics
$5.42 /

-0.49 (-8.29%)

Earnings
Kingstone Companies reports Q2 operating EPS 23c, consensus 22c » 16:18
08/06/20
08/06
16:18
08/06/20
16:18
KINS

Kingstone Companies

$5.72 /

+0.13 (+2.33%)

Reports direct written…

Reports direct written premiums from personal lines grew by 9.1%; Direct written premiums, including commercial liability lines in run off, decreased by 4.8%. Net premiums earned from personal lines decreased by 4.9%; Net premiums earned, including commercial liability lines in run off, decreased 14.6% to $26.6M. Net loss ratio, excluding commercial liability lines in run off1, of 47.1% compared to 50.5%; Net loss ratio, including commercial liability lines in run off, of 48.1% compared to 56.6%. Net combined ratio of 87.3% compared to 94.1%.

ShowHide Related Items >><<
KINS Kingstone Companies
$5.72 /

+0.13 (+2.33%)

KINS Kingstone Companies
$5.72 /

+0.13 (+2.33%)

KINS Kingstone Companies
$5.72 /

+0.13 (+2.33%)

Earnings
Pacira reports preliminary July sales of Exparel of $38.1M » 08:10
08/06/20
08/06
08:10
08/06/20
08:10
PCRX

Pacira

$56.09 /

+0.83 (+1.50%)

Pacira reported…

Pacira reported preliminary unaudited net product sales of Exparel and iovera of $38.1M and $0.8M, respectively, for the month of July 2020. "Given the rapidly changing variables related to the COVID-19 pandemic, the company does not have sufficient visibility to accurately forecast the impact of the pandemic and is currently not providing full-year 2020 financial guidance. In order to provide greater transparency, the company plans to report monthly intra-quarter unaudited net product sales until it has gained sufficient visibility around the impacts of COVID-19," the company said.

ShowHide Related Items >><<
PCRX Pacira
$56.09 /

+0.83 (+1.50%)

PCRX Pacira
$56.09 /

+0.83 (+1.50%)

07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
PCRX Pacira
$56.09 /

+0.83 (+1.50%)

PCRX Pacira
$56.09 /

+0.83 (+1.50%)

Earnings
Pacira reports Q2 EPS 12c, consensus 9c » 08:08
08/06/20
08/06
08:08
08/06/20
08:08
PCRX

Pacira

$56.09 /

+0.83 (+1.50%)

Reports Q2 revenue…

Reports Q2 revenue $75.5M, consensus $72.5M. "We are very pleased to report that since the peak of the impact from COVID-19 in April, we've seen a steady and continued increase in EXPAREL sales. This is a testimony to the resolve of our physician partners who are dedicated to ensuring that patients receive their much-needed surgeries, particularly in the ambulatory setting. This pandemic has accelerated the shift of inpatient procedures to the 23-hour stay environment and we are well positioned to lead the way with our innovative opioid alternatives. Today, we are in a stronger position than ever as we wind down our partnership with DePuy Synthes and take full ownership of the EXPAREL franchise. Our recent financing strengthens our financial foundation and supports our strategy to expand our footprint in non-opioid pain management and regenerative health solutions while simultaneously ramping the top and bottom lines," said Dave Stack, chairman and CEO of Pacira BioSciences.

ShowHide Related Items >><<
PCRX Pacira
$56.09 /

+0.83 (+1.50%)

PCRX Pacira
$56.09 /

+0.83 (+1.50%)

07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
PCRX Pacira
$56.09 /

+0.83 (+1.50%)

PCRX Pacira
$56.09 /

+0.83 (+1.50%)

Wednesday
Hot Stocks
Pacira announces publication of Phase 4 study of EXPAREL » 07:42
08/05/20
08/05
07:42
08/05/20
07:42
PCRX

Pacira

$55.26 /

+0.38 (+0.69%)

Pacira BioSciences…

Pacira BioSciences announced that full results its Phase 4 study of EXPAREL administered via transversus abdominis plane field block in patients undergoing Cesarean section have been published in Anesthesia and Analgesia. In this study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours. EXPAREL also achieved statistical significance for reduction in percentage of opioid-spared patients through 72 hours. This was a multicenter, randomized, double-blind study across 13 clinical sites in the United States, in patients undergoing elective C-section and receiving spinal anesthesia and a multimodal analgesic regimen. Patients were randomized to receive EXPAREL 266 mg plus bupivacaine HCl 50 mg or bupivacaine HCl 50 mg alone administered via TAP field block after delivery. Effectiveness was evaluated in a pre-specified modified intent-to-treat population which met the study criteria regarding proper administration of TAP and multimodal regimen. Key findings include: Significant reduction in total opioid consumption with EXPAREL plus bupivacaine HCl versus bupivacaine HCl. 52% reduction through 72 hours, the primary endpoint of the study. 49% reduction at one week. 41% reduction of opioid consumption at two weeks, although results did not reach statistical significance. Significantly higher percentage of opioid-spared patients with EXPAREL versus bupivacaine HCl, defined as patients who took no more than one oxycodone 10 mg tablet with no opioid-related side effects through 72 hours. Percentage of opioid-spared patients was 2.2 times higher in the EXPAREL group vs bupivacaine HCl group. Optimized pain control through 72 hours, which was comparable in both groups. Patients in the EXPAREL arm of this study were administered a TAP field block with 10 mL EXPAREL admixed with 10 mL 0.25% bupivacaine HCl and 10 mL normal sterile saline injected bilaterally. Patients in the active comparator arm received a TAP field block with 10 mL 0.25% bupivacaine HCl admixed with 20 mL normal sterile saline injected bilaterally. Research shows nearly nine in 10 mothers and mothers-to-be have concerns about taking opioids during and after childbirth, yet 51% of all C-section patients are prescribed an opioid to manage postsurgical pain. Prior to C-section, all patients in this study received an intrathecal injection of 150 mcg preservative-free morphine for spinal injection in conjunction with single-shot spinal anesthesia using 1.4-1.6 mL bupivacaine HCl 0.75% and 15 mcg fentanyl. Following C-section, patients also received an opioid-sparing multimodal analgesic regimen which consisted of 15 mg of intravenous ketorolac, 1000 mg of IV acetaminophen at the time of skin incision closure, and scheduled oral acetaminophen and ibuprofen beginning 6 hours after skin incision closure for up to 72 hours following surgery. Rescue medication was available upon request and postsurgical opioid consumption was collected. Safety was comparable between study groups, with 64 percent of patients in the EXPAREL group experiencing a treatment-emergent adverse event versus 56 percent of patients in the bupivacaine HCl group. The most common TEAEs include pruritus and nausea; serious TEAEs were rare. There were no fatal TEAEs. Earlier this year, Pacira announced positive topline results for CHOICE, a next-generation C-section trial designed to eliminate the use of spinal morphine in the EXPAREL arm. In the study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total opioid consumption while maintaining pain scores through 72 hours, and demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery.

ShowHide Related Items >><<
PCRX Pacira
$55.26 /

+0.38 (+0.69%)

PCRX Pacira
$55.26 /

+0.38 (+0.69%)

07/13/20 H.C. Wainwright
Pacira price target raised to $68 from $63 at H.C. Wainwright
07/10/20 Jefferies
Pacira price target raised to $69 from $53 at Jefferies
07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
PCRX Pacira
$55.26 /

+0.38 (+0.69%)

PCRX Pacira
$55.26 /

+0.38 (+0.69%)

Earnings
Parsons backs FY20 revenue view $3.95B-$4.05B, consensus $4.02B  06:47
08/05/20
08/05
06:47
08/05/20
06:47
PSN

Parsons

$35.46 /

-0.28 (-0.78%)

 
ShowHide Related Items >><<
PSN Parsons
$35.46 /

-0.28 (-0.78%)

PSN Parsons
$35.46 /

-0.28 (-0.78%)

05/05/20 Wells Fargo
Parsons price target raised to $39 from $33 at Wells Fargo
04/15/20 Benchmark
Parsons initiated with a Buy at Benchmark
04/02/20 Wells Fargo
Parsons price target lowered to $33 from $42 at Wells Fargo
03/30/20 William Blair
Parsons initiated with an Outperform at William Blair
PSN Parsons
$35.46 /

-0.28 (-0.78%)

PSN Parsons
$35.46 /

-0.28 (-0.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.